HUDDINGE, Sweden, Feb. 14, 2003 (PRIMEZONE) -- Medivir (Stockholm:MVIRb):
- MIV-606 (now RP-606) outlicensed to Reliant Pharmaceuticals in
February
- MV026048 outlicensed to Roche in April
- MIV-310 achieved positive clinical results against multiresistant
HIV
- MIV-210 against HIV and hepatitis B, as well as cathepsin S in
immunological diseases, produced positive preclinical results
- In December, Medivir and Paradigm entered a three-year
collaboration within protease research
- The Board of Directors appointed Bo Oberg CEO in December, for
the period January 1 to March 1 when Lars Adlersson takes up
position as Medivir's CEO and President.
- An Extraordinary General Meeting in December approved the
2002/2007 staff stock option plan
- Profit after financial items amounted to SEK -64.2 (-139.4) m;
net sales rose to SEK 256.3 (125.9) m
- CCS achieved net sales gains to SEK 153.3 (126.4) m; operating
profit was SEK 22.4 (16.4) m
Forthcoming Financial Reports
The Annual General Meeting will be on April 29, 2003
The First-quarter Interim Report 2003 will be published on
April 29, 2003.
The second-quarter Interim Report 2003 will be published on July 9, 2003.
Medivir's financial reports are available from its Website, www.medivir.com as of these dates, under the "Financial Information" heading.
For more information, please contact:
Bo Oberg, CEO and President Tel: +46 (0)8 5468 3100 Rein Piir, CFO and VP, IR tel: +46 (0)8 5468 3123 or +46 (0)70 853 7292
The Medivir Group
Medivir is an innovative, specialist pharmaceuticals research and development corporation, located in Cambridge, U.K. and Huddinge, Sweden. Medivir's research is focused on developing new pharmaceutical substances based on proteases and polymerases as target enzymes.
The group comprises Medivir AB, the subsidiaries Medivir U.K. Ltd. and CCS AB, plus second-tier subsidiaries CCS (U.K.) Ltd. and Nordic Care Sweden AB. Medivir has been quoted on the Stockholm Stock Exchange since 1996.
Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma, MS (multiple sclerosis) and organ/transplantation rejection. Medivir has four projects in clinical development phases, two of which are entering phase III after completing phase II. One project is in phase I and one is in phase II. Medivir's preclinical research encompasses a number of projects, one of which is in late preclinical development, one is entering, and one is in, the optimization phase and one is in the model substance identification phase. Additionally, Medivir has some fifteen activities in explorative phases.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
www.waymaker.net/bitonline/2003/02/14/20030214BIT00620/wkr0001.doc The Full Report